The UK and US have finalized a significant bilateral deal that will preserve zero import taxes on UK drug products going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to boost funding on medicines through the National Health Service (NHS). This pledge ensures that import taxes on these key exports will remain at nothing for a duration of the next three years.
This agreement comes after earlier threats to significantly raise import taxes on branded pharmaceutical products, with potential rates floated as high as 100%.
"This agreement between the UK bolsters the international landscape for new treatments and introduces long-overdue equity to transatlantic pharmaceutical trade," a release declared.
Trade Significance
Drugs represent one of the the United Kingdom's biggest exports to the US, which is clearly the biggest market for large companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period to the end of the third quarter, the UK exported medicines totaling billions to the US. This figure represented 17.4% of all goods exports in that span.
"This deal secures employment, increases investment and sets the stage for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The deal involves several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to raise overall NHS spending on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. In the past, repayments topped twenty percent.
Recent Tensions
The deal follows a ongoing row between the drug companies and the ministers over drug pricing and NHS adoption.
The disagreement were intensified by claims that American patients were charged a premium for the identical medicines than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been halted or scrapped, while substantial funding commitments have been directed toward American operations.
The Science Minister publicly accepted that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the past decade.
